Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
Molecular Weight | 910.0 g/mol |
---|---|
Molecular Formula | C29H44ClN5O18P4 |
Hydrogen Bond Donor Count | 14 |
Hydrogen Bond Acceptor Count | 23 |
Rotatable Bond Count | 6 |
Exact Mass | 909.1320353 g/mol |
Monoisotopic Mass | 909.1320353 g/mol |
Topological Polar Surface Area | 380 A^2 |
Heavy Atom Count | 57 |
Formal Charge | 0 |
Complexity | 1130 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 5 |
Date of Issue : 2020-06-11
Valid Till : 2023-06-10
Written Confirmation Number : WC-0473
Address of the Firm :
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The grant will support research and development efforts aimed at improving the technology and efficiency of pyronaridine production for pyronaridine-artesunate combination therapy, Pyramax.
Lead Product(s): Pyronaridine Tetraphosphate,Artesunate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Pyramax
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Medicines for Malaria Venture
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Funding August 27, 2024
Lead Product(s) : Pyronaridine Tetraphosphate,Artesunate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Medicines for Malaria Venture
Deal Size : $0.2 million
Deal Type : Funding
Mangalam Drugs & Organics Awarded US$ 274,800 Grant by MMV
Details : The grant will support research and development efforts aimed at improving the technology and efficiency of pyronaridine production for pyronaridine-artesunate combination therapy, Pyramax.
Brand Name : Pyramax
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 27, 2024
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?